Background Angiogenesis has been recognized as the most important factor for tumor
invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC).
However, few clinical data are available regarding the efficacy of cabozantinib following
immunotherapy. Objective To describe the outcome of cabozantinib in patients previously
treated with immunotherapy. Patients and methods Patients with mRCC who received
cabozantinib immediately after nivolumab were included. The primary endpoint was to …